Shanghai Junshi Biosciences Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

16.22

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

10.36%

Rev. gr., 5y

337.82%

Revenues

1.50b

+3.38%

Net income

-2.28b

L-11.64%

CFO

-2.01b

L+13.50%

Profile

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

URL

https://www.junshipharma.com/

IPO date

Dec 24, 2018

Employees

2,772

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	1,502,550 3.38%	1,453,493 -63.89%	4,024,841 152.36%
Cost of revenue	4,005,924	4,204,628	4,709,439
Unusual Expense (Income)
NOPBT	(2,503,374)	(2,751,135)	(684,598)
NOPBT Margin
Operating Taxes	43,995	(93,107)	135,533
Tax Rate
NOPAT	(2,547,369)	(2,658,028)	(820,131)
Net income	(2,281,624) -11.64%	(2,582,095) 254.60%	(728,181) -56.28%
Dividends		(19,158)	(16,691)
Dividend yield		0.04%	0.03%
Proceeds from repurchase of equity	125,704	3,831,422	2,166,818
BB yield	-0.66%	-8.61%	-4.19%
Debt
Debt current	575,322	435,414	45,068
Long-term debt	1,266,627	976,416	710,726
Deferred revenue		121,615	118,776
Other long-term liabilities	370,614	7,504	(490,000)
Net debt	(3,069,305)	(5,987,942)	(3,872,172)
Cash flow
Cash from operating activities	(2,014,964)	(1,775,325)	(641,901)
CAPEX	(832,575)	(393,952)	(886,228)
Cash from investing activities	(892,422)	(467,619)	(1,880,952)
Cash from financing activities	681,041	4,643,009	2,665,686
FCF	(3,228,675)	(2,453,153)	(1,963,944)
Balance
Cash	3,778,142	5,996,936	3,504,605
Long term investments	1,133,112	1,402,836	1,123,361
Excess cash	4,836,126	7,327,097	4,426,724
Stockholders' equity	(8,047,058)	1,275,706	(3,106,340)
Invested Capital	17,509,688	9,934,057	11,614,553
ROIC
ROCE
EV
Common stock shares outstanding	985,302	917,465	892,660
Price	19.44 -59.92%	48.50 -16.38%	58.00 11.65%
Market cap	19,154,274 -56.95%	44,497,061 -14.06%	51,774,262 20.83%
EV	16,254,356	38,870,361	48,273,369
EBITDA	(2,200,154)	(2,457,481)	(422,039)
EV/EBITDA
Interest	29,006	29,370	21,833
Interest/NOPBT